Insider · CIK 0001533022
Mahoney Michael F
ceopresidentchairofficerdirector
Files at CVS (CVS HEALTH Corp), BSX (BOSTON SCIENTIFIC CORP). First filing Nov 7, 2024, latest Nov 7, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $14M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 30Weak | sell 310b5-1 | BSX BOSTON SCIENTIFIC CORP | $14M | 162,778 | -10% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | BSX BOSTON SCIENTIFIC CORP | GGift Common Stockindirect: By Trust | -7,800 | $0.00 | $0 | 201,478 | Nov 27, 2024 |
| Nov 21, 2024 | CVS CVS HEALTH Corp | AGrant or award Common Stock | +2,200 | $57.10 | $126k | 6,201 | Nov 25, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | MOption exercise Common Stock10b5-1 | +56,211 | $17.26 | $970k | 1,628,307 | Nov 7, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | MOption exercise Common Stock10b5-1 | +55,676 | $16.31 | $908k | 1,683,983 | Nov 7, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | SOpen-market sale Common Stock10b5-1 | -2,596 | $85.17 | $221k | 1,681,387 | Nov 7, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | SOpen-market sale Common Stock10b5-1 | -160,182 | $84.74 | $14M | 1,521,205 | Nov 7, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -56,211 | $0.00 | $0 | 168,635 | Nov 7, 2024 |
| Nov 5, 2024 | BSX BOSTON SCIENTIFIC CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -55,676 | $0.00 | $0 | 0 | Nov 7, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.